{
  "documentMetadata": {
    "title": "Osteomyelitis, Vascular Insufficiency",
    "lastUpdated": "2024-04-12",
    "sourceFile": "Osteomyelitis, Vascular Insufficiency.pdf"
  },
  "content": [
    {
      "type": "header",
      "level": 1,
      "text": "Clinical Setting"
    },
    {
      "type": "list",
      "items": [
        "Diabetics with peripheral neuropathy and infected skin ulcers",
        "Peripheral vascular disease",
        "Diagnosis",
        "Culture of bone biopsy; swab cultures unreliable (Clin Infect Dis 42:57, 2006).",
        "Osteomyelitis is more likely if ulcer >2 cm², positive probe to bone, ESR >70 and abnormal plain x-ray (JAMA 299:806, 2008).",
        "See also Diabetic Foot."
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Etiologies"
    },
    {
      "type": "list",
      "items": [
        "Staphylococcus aureus",
        "Streptococci",
        "Anaerobes (Gram-positive and Gram-negative)",
        "Gram-negative bacilli",
        "Polymicrobial"
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Primary Regimens"
    },
    {
      "type": "list",
      "items": [
        "Debride overlying ulcer and submit bone for histology and culture.",
        "Select antibiotic based on culture results and treat for 6 weeks if unresected, infected bone and 2-5 days with definitive radical resection of infected bone.",
        "Empirical therapy pending culture data (NOT recommended unless patient is acutely ill)",
        "Vancomycin 15-20 mg/kg IV q8-12h to achieve preferred target AUC24 400-600 µg/mL x hr (see vancomycin AUC dosing calculator; alternative is trough of 15-20 µg/mL) + Ertapenem 1 gm q24h OR",
        "Vancomycin as above + Moxifloxacin 400 mg IV/po once daily",
        "See also: Diabetic Foot.",
        "Revascularization if possible."
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Alternative Regimens"
    },
    {
      "type": "list",
      "items": [
        "Oral agent(s) with good bioavailability (e.g., TMP-SMX, a fluoroquinolone, Doxycycline, Linezolid, Amoxicillin-clavulanate, Clindamycin) that have activity against bone isolates are suitable alternatives to parenteral therapy (See Expert Opin Pharmacother. 2017; 18:759)."
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Antimicrobial Stewardship"
    },
    {
      "type": "list",
      "items": [
        "If possible avoid empiric therapy prior to obtaining cultures to maximize yield of microbiological studies.",
        "De-escalate and refine regimen based on microbiological data."
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Comments"
    },
    {
      "type": "list",
      "items": [
        "IDSA Guidelines for diabetic foot infection: Clin Infect Dis. 2023 Oct 2:ciad527."
      ]
    }
  ]
}